spacer
home > > summer 2019 > preparations for the new eu portal
PUBLICATIONS


Preparations for the New EU Portal





The EMA is developing a new clinical trial information system (CTIS) that will provide a single portal for submitting and managing clinical trial application (CTA) dossiers, authorisations, and transparency. While this new system is not expected to be live until late in 2020, organisations should be preparing now for the significant process and systems changes that the CTIS will require.

Before a clinical trial can be conducted in the EU, a dossier must be submitted for approval. Once approved, a trial requires the submission of protocol amendments, status updates, and results information after the trial has completed. For trials with paediatric participants, results are required within six months of the end of trial, while trials in adults require results within 12 months.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


As TrialScope’s Chief Strategy Officer, Thomas Wicks is responsible for the strategy of clinical trial disclosure and transparency solutions. He has more than 20 years of experience with performance and content management solutions, specialising in applications for life sciences such as clinical trial disclosure, structured product labelling, and submissions management. He has been focused on trial transparency since 2007.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement